RACHEL LUBER: Open Payments
NPI 1376106807 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$814 in 43 payments from 19 companies in 2025. Trend: 2023 $883 · 2024 $598 · 2025 $814
Food & beverage: $814
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 5 | $120 |
| ANI Pharmaceuticals, Inc. | 5 | $109 |
| Vifor Pharma, Inc. | 4 | $66 |
| Novo Nordisk Inc | 3 | $65 |
| Travere Therapeutics, Inc. | 7 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $54 |
| Novartis Pharmaceuticals Corporation | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
Products named: TARPEYO, PURIFIED CORTROPHIN GEL, Veltassa, Ozempic, Kerendia, Vanrafia, JYNARQUE, JARDIANCE.
Industry payments across MO — which companies pay providers there.
